Industries / Healthcare / Pharmaceutical / Hemophilia Drugs Market

"Catapult Your Business to Fore, Gain Competitive Advantage "

Hemophilia Drugs Market Size, Share and Global Trend By Disease Indication (Hemophilia A, B & C), Therapy Type (Recombinant Therapy, Plasma therapy & Others), Distribution Channels (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) and Geography Forecast till 2025

Report Format: PDF | Latest Update: May, 2019 | Published Date: Apr, 2019 | Report ID: FBI100068 | Status : Published

 

REPORT OVERVIEW

The Global Hemophilia Drugs Market, which was valued at US$ 9,875.4 Mn in 2017, is projected to reach US$ 15,830.3 Mn by the end of 2025, exhibiting a CAGR of 6.0%. The rising burden of rare disorders among people globally is a major concern for the healthcare field. Hemophilia is one of the rarest bleeding disorders in which blood lacks sufficient blood clotting factors. Patients suffering from hemophilia usually bleed abnormally and for a longer time than other people, as the abnormality in the hemophilia gene slows the blood clotting process.

Hemophilia is generally caused by gene mutation, and around 70% of the hemophilia cases are inherited. Increasing awareness of such rare diseases among the population and government participation in the prevention and control of these life-threatening diseases are the key factors associated with the estimated growth of hemophilia drugs market. Moreover, rising investment by key pharmaceutical companies in R&D of novel therapies for hemophilia is propelling the expansion of hemophilia drugs market at a remarkable rate. 

Get comprehensive study about this report by, request a sample copy

Hemophilia A to Emerge as Most Attractive Disease Indication to Invest In

Hemophilia has 3 types, which are hemophilia A, B, and C, out of which the incidence rate for hemophilia A and B is relatively significant. The annual cost of care associated with the hospitalization and medications for hemophilia A treatment is considerably high. The green signal by regulatory authorities for major brands such as Humira in mid of 2017 has improved the hemophilia A treatment scenario across the globe. Hemophilia A accounted for a market share of 85.0% in 2017. The high cost of Humira and other drugs for hemophilia A treatment, and considerable patient pool for disease type is expected to augment the growth of hemophilia A segment in terms of revenue during the forecast period.

To get details on market share, speak to our analyst

In terms of therapy type, the hemophilia drugs market is categorized into recombinant therapy, plasma-derived, and others. The recombinant therapy accounted for maximum market share in 2017, owing to the improved outcome of recombinant therapeutics over the plasma-derived. However, others segment, which is comprised of gene therapy, biospecific drugs, and other such drugs is anticipated to witness a relatively high growth rate during the forecast period. Various distribution channels covered under the report are hospital pharmacy, retail pharmacy, and online pharmacy.

Improved Distribution Network of Pharmaceutical Giants Enables Market to Exhibit Highest CAGR in Asia Pacific

North America generated maximum revenue of US$ 3,684.7 Mn in 2017 and is expected to dominate the market throughout the forecast period. Strategies of key pharmaceutical companies in the U.S. and rising prevalence of hemophilia A & B in the U.S. and Canada are projected to boost the expansion of hemophilia drugs market in North America during 2017-2025. Europe is anticipated to be the second most prominent region in terms of revenue by 2025. However, Asia Pacific is likely to register highest CAGR during the forecast period, attributable to the green signal by regulatory authorities in Australia and Japan for the approval of novel therapeutics for hemophilia A and improved funding by public & private players for the improvisation of healthcare facilities in India and China.

North America Hemophilia Drugs Market, 2017

To get geographical overview of this market, request a sample copy

Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd, and Novo Nordisk to Account for More Than Half of the Market Share in Terms of Revenue

Takeda Pharmaceutical Company Limited has emerged as a leading player in the global hemophilia drugs market after acquiring Shire Plc, a leader in the bleeding disorder therapeutics. Takeda is estimated to retain its position in the forecast duration owing to its efficient business expansion strategies that are currently being implemented in potential countries. This company together with F. Hoffmann-La Roche Ltd and Novo Nordisk currently holds over half of the market share in terms of revenue. Other players operating in the global hemophilia drugs market are Pfizer, Inc., CSL Limited, Grifols, S.A., Bioverativ Inc., Octapharma AG, FERRING LÄKEMEDEL AB, and Aptevo Therapeutics.

REPORT OVERVIEW

With adequate and effective treatment, a patient suffering from hemophilia can live a healthy life. The missing clotting factors are injected into the patient’s bloodstream to cease the abnormal bleeding. With numerous innovative therapeutic options in the pipeline, the hemophilia drugs industry is expected to witness remarkable growth in near future.

The report provides qualitative and quantitative insights on the hemophilia drugs industry and detailed analysis of market size and growth rate for all possible segments in the market. The market is segmented by therapy type, disease indication, and distribution channel. On the basis of therapy type, the global hemophilia drugs market is segmented into recombinant therapy, plasma-derived, and others. In terms of disease indication, the market is categorized into hemophilia A, hemophilia B, and hemophilia C. Various distribution channels covered under the report are hospital pharmacy, retail pharmacy, and online pharmacy. Geographically, the market is segmented into five major regions, which are North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions are further categorized into countries.

Along with this, the report provides elaborative analysis of the market dynamics and competitive landscape. Various key insights provided in the report are the prevalence of coagulation factor deficiency and hemophilia, recent industry developments such as mergers & acquisitions, the regulatory scenario in key countries, new products launch, pipeline analysis, reimbursement scenario, and key industry trends.

KEY SEGMENTS WITHIN THE MARKET

To get information on various segments, share your queries wth us

 SEGMENTATION

 DETAILS

By Disease Indication

·      Hemophilia A

·      Hemophilia B

·      Hemophilia C

By Therapy Type

·      Recombinant Therapy

·      Plasma therapy

·      Others

By Distribution Channels

·      Hospital Pharmacy

·      Retail Pharmacy

·      Online Pharmacy

By Geography

·      North America (USA and Canada)

·      Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)

·      Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)

·      Latin America (Brazil, Mexico and Rest of Latin America)

·      Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)

KEY COMPANIES COVERED IN THE REPORT

  • Grifols SA
  • CSL Behring
  • Octapharma AG
  • Pfizer, Inc.
  • Bioverativ Inc.
  • FERRING LÄKEMEDEL AB
  • Aptevo Therapeutics
  • Takeda Pharmaceutical Company Limited
  • Hoffmann-La Roche Ltd
  • Novo Nordisk
  • Other players

  • Global
  • 2018
  • 2014-2018
  • PRICE
  • 4850
    6850
    8850
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . More info.
X